What the research shows
In a randomized phase 2 trial, 338 adults received investigational retatrutide or placebo. Average weight change at 48 weeks ranged from −8.7% to −24.2% across treatment groups, compared with −2.1% with placebo. Gastrointestinal side effects occurred more often at higher exposures. Placebo-controlled phase 2 trial.
The FDA identifies retatrutide as an unapproved active ingredient. The published trial concerns the investigational product supplied to participants. FDA on unapproved GLP-1 drugs.
Documented formats
The clinical trial used an investigational injectable preparation under controlled conditions.
Testing and purity
To connect a sample to this research, look for a lot-linked identity test for LY3437943 that accounts for the peptide sequence and its attached lipid group.
How to read a batch reportQuestions about Retatrutide
What did the trial measure first?
Its primary outcome was percentage change in body weight at 24 weeks. The often-quoted 48-week figure was a secondary outcome.
Was the comparison against tirzepatide?
The control group received placebo. Ranking the two compounds would require a direct comparison or a carefully designed indirect analysis.